Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab.
Wayne GulliverAfsaneh AlaviMarni C WisemanMelinda J GooderhamJaggi RaoMaryam Shayesteh AlamKim A PappOlivier DesjardinsChristine JeanPublished in: Journal of cutaneous medicine and surgery (2022)
At week 24 and maintained at week 52 in a real-world setting, adalimumab meaningfully improved HRQoL, work productivity, and activity impairment in moderate-to-severe HS patients.
Keyphrases
- hidradenitis suppurativa
- end stage renal disease
- rheumatoid arthritis
- ejection fraction
- high intensity
- early onset
- chronic kidney disease
- newly diagnosed
- climate change
- prognostic factors
- peritoneal dialysis
- clinical trial
- randomized controlled trial
- ulcerative colitis
- patient reported outcomes
- systemic lupus erythematosus
- placebo controlled
- patient reported